ABSTRACT Background: Zinc is an essential micronutrient for human health and has numerous structural and biochemical roles. The search for a reliable, sensitive, and specific index of zinc status has been the subject of considerable research, which has resulted in the identification of a number of potentially useful biomarkers. Objective: The objective was to assess the usefulness of biomarkers of zinc status in humans. Design: The methods included a structured search strategy using Ovid MEDLINE, EMBASE (Ovid), and the Cochrane Library CENTRAL databases; formal inclusion and exclusion criteria; data extraction into an Access database; quality and validity assessment; and meta-analysis. Results: Data on 32 potential biomarkers from 46 publications were analyzed. Plasma zinc concentration responded in a dose-dependent manner to dietary manipulation in adults, women, men, pregnant and lactating women, the elderly, and those at low and moderate baseline zinc status. Urinary zinc excretion responded to zinc status overall and in all subgroups for which there were sufficient data. Hair zinc concentration also responded, but there were insufficient studies for subgroup analysis. Platelet, polymorphonuclear cell, mononuclear cell, and erythrocyte zinc concentration and alkaline phosphatase activity did not appear to be effective biomarkers of zinc status. Conclusions: This systematic review confirms that in healthy individuals, plasma, urinary, and hair zinc are reliable biomarkers of zinc status. Further high-quality studies using these biomarkers are required, particularly in infants, adolescents, and immigrant population groups for whom there are limited data. Studies are also required to fully assess a range of additional potential zinc biomarkers.
INTRODUCTION
Zinc is well established as an essential micronutrient for human health because it has numerous structural and biochemical functions at the cellular and subcellular level, which include enzyme function, DNA and RNA metabolism, protein synthesis, gene expression, cell growth and differentiation, and cellmediated immunity. The ubiquitous nature of zinc in human biological systems indicates the widespread consequences and the complexity of inadequate dietary supply of zinc and zinc depletion.
Zinc is absorbed in the small intestine, primarily via transportermediated processes. Rich sources of dietary zinc include meat, fish, shellfish, nuts, seeds, legumes, and whole-grain cereals (1, 2) . However, plant sources are considered to be less bioavailable because of the presence of phytic acid that binds to zinc-forming insoluble complexes, which thus inhibits zinc's absorption (1) . The current recommendations for dietary zinc intake in adults range from 7 mg/d (UK Reference Nutrient Intake) to 11 mg/d (US Recommended Dietary Allowance) (2) . This broad range reflects in part the variation in requirements due to differences in the bioavailability of zinc from different national diets and also the difficulties associated with estimating the requirements for optimal health, which depends on a reliable indicator of status (3) .
Unlike other micronutrients such as iron, there is no storage form of zinc in the body that can be readily mobilized when intakes are inadequate, which emphasizes the need for a regular dietary supply (4) . A highly effective homeostatic mechanism responds to alterations in zinc intake, upregulating absorption and conserving losses via the gastrointestinal tract and kidneys when intakes fall. By using isotope tracer techniques, it was predicted that when dietary zinc fell from 12.2 to 0.23 mg/d in a group of adult men, fractional zinc absorption could increase to virtually 100%, with urinary excretion falling from 0.36 to 0.006 mg/d and fecal excretion falling from 11.8 to 0.23 mg/d (4) . When homeostatic mechanisms fail to ensure that requirements are met, clinical symptoms of zinc deficiency ensue. Severe deficiency is associated with stunted growth, immune dysfunction, and poor wound healing. These symptoms of severe zinc deficiency are most dramatically observed in acrodermatitis enteropathica, a congenital condition in which the infant is born with impaired gastrointestinal zinc transport, which limits the ability to absorb zinc (5) . In European populations, severe primary zinc deficiency is extremely uncommon, but marginal deficiency is likely to be much more prevalent (6) . The lack of a reliable, responsive, and specific indicator of zinc status means that the diagnosis of marginal zinc deficiency is difficult.
The aim of this systematic review was to assess the usefulness of the biomarkers of zinc status in healthy humans to determine which biomarkers appropriately reflect changes in zinc status in response to supplementation or depletion.
METHODS

Inclusion criteria
Both supplementation and depletion studies were included in our search. The forms of zinc used for supplementation included zinc sulfate, gluconate, methionine, and acetate, all of which have been shown to be readily absorbable (7) . For the purposes of this review, a minimum duration of the supplementation or depletion intervention of 2 wk was deemed sufficient to elicit a biomarker response. This decision was based on a study of zinc depletion and repletion in men, where there was an increase in plasma zinc concentration of 260% within 1 wk of the reintroduction of zinc to the diet after a period of depletion with very little further increase in plasma zinc concentration after 2 wk (8).
Types of study
To be included, a study needed to meet all of the following criteria: 1) be an intervention study in humans (including supplementation and/or depletion studies) without restriction in study design, which could include randomized controlled trials (RCTs), controlled clinical trials, and before-after studies (B/A); 2) report the zinc status in humans at baseline and after supplementation or depletion; 3) span a time period of !2 wk over which the change was measured; 4) report the daily dose of the zinc supplement; 5) use one of the following supplements: zinc sulfate; zinc acetate; zinc gluconate, or zinc methionine; and 6) involve healthy participants who had not recently used mineral or vitamin supplements.
Search strategy
Electronic searches were performed with Ovid MEDLINE (www.ovid.com), EMBASE (Ovid; www.ovid.com), and the Cochrane Library CENTRAL (www.thecochranelibrary.com) database, which were searched from inception to October 2007 for intervention studies by using text terms with appropriate truncation and relevant indexing terms. The search was in the form: [zinc terms] and [intervention study terms] and [human studies]. The full Ovid MEDLINE search strategy can be found in Table S1 under ''Supplemental data'' in the online issue. The searches of the above-mentioned databases were also based on this strategy.
An Ovid MEDLINE search was conducted for reviews of the methods of assessing zinc status; 6 of these reviews (9) (10) (11) (12) (13) (14) were collected in full text, and the reference lists were checked. Studies that appeared to be intervention studies but that had not been already assessed for inclusion were collected.
One expert, Rosalind Gibson, was asked if she could suggest additional intervention studies for the review. She suggested additional articles for assessment and these were then subjected to the same criteria listed above before they were accepted for inclusion.
Data extraction
The methodology of this review is based on the standard methodology developed for this set of reviews in this supplement (15) and is abbreviated below, mainly noting differences from the main methodology. Titles and abstracts were screened for inclusion by a single reviewer (KF). The full text of all articles collected was screened for inclusion by using an inclusion and exclusion form by 2 independent reviewers. Where the 2 reviewers disagreed, the study was discussed and a consensus decision was reached, or a third reviewer was asked to arbitrate.
Data for each included study were extracted onto an Access (Microsoft Corp, Redmond, WA) database file by a single reviewer (KF). In doubtful cases, studies were discussed with the review team before beginning full data extraction and, in some cases, study authors were contacted for clarification. When necessary, units of measurement were converted to a standard form to facilitate comparison across studies. Data extraction and synthesis for primary and secondary measures of interest were undertaken as discussed in the methodology article (15) .
RESULTS
The flow diagram for this review is shown in Figure 1 . A total of 1334 titles and abstracts were screened after electronic and bibliographic searches or were recommended by experts. Of these, 182 appeared potentially relevant and were collected as full-text articles to be assessed for inclusion, and 180 full-text articles were assessed (2 articles could not be traced); 48 studies were found to fulfill the inclusion criteria. One article had elements of both an RCT and a B/A in the study design (16) and one article contained a supplementation and a depletion study (17) . These data were analyzed as 2 separate studies, giving a total of 48 studies from 46 publications: 24 described RCT studies and 24 described B/A studies. In some cases, studies were further subdivided into data sets, when, for example, the study cohort was assigned to groups receiving different amounts of supplementation.
Quality of included studies
The characteristics of the studies included in the analysis are presented in Table 1 (supplementation studies) and Table 2 (depletion studies). In terms of the distribution of the age of the population groups studied, 67% (32/48) of the studies were in healthy adults, and 19% (9/48) in elderly people. There were 5 studies in pregnant or lactating women (36, 38, 43, 48, 49) , one study in postmenopausal women (58) , and one study in children and adolescents (40) . There were no studies in infants, and none that selected for immigrant or low-socioeconomic groups. As discussed in the methodology article (15) , quality assessment was undertaken as part of the data extraction process. A summary of the reasons for dropping out in the intervention group, the methods of randomization, and compliance checking are summarized in Table 3 . In the majority of studies, the reasons for dropping out and the method and outcome of compliance testing were not reported. In studies that claimed to be randomized, only 2 of 26 described the methods used.
Biomarkers identified
In the 48 studies included in this review, a total of 32 potential zinc biomarkers, 17 biomarkers of zinc status in zinc supplementation trials, and 25 biomarkers in zinc depletion trials were identified. A summary of all the biomarkers identified, including the number of studies, participants, and the results of the primary analysis where relevant is presented in Table 4 . A large proportion of the studies included in this review measured plasma or serum zinc concentration, and for simplicity, here the term ''plasma'' will be used to refer to both. The results of the secondary analysis of biomarkers for which there were sufficient data for subgroup analysis are described below.
Plasma zinc concentration
Plasma zinc concentration was the most frequently investigated marker of zinc status, with a total of 40 data sets from 35 supplementation studies, which involved 1375 participants and 10 data sets from 10 depletion studies involving 79 participants. Combining data from the depletion and supplementation studies, primary analysis revealed an overall significant (P , 0.00001) response of plasma zinc concentration to dietary zinc intake [weighted mean difference (WMD): 2.9 lmol/L; 95% CI: 2.2, 3.5; I 2 ¼ 94%] (see Figure S1 under ''Supplemental data'' in the online supplement), but with high levels of heterogeneity between studies. A summary of the subgroup analysis of the response of plasma zinc concentration to zinc supplementation and depletion is given in Table 5 . The data included in this analysis were mostly collected from studies in adults and the elderly. The response of plasma zinc concentration to supplementation was significant in adults, the elderly, pregnant and lactating women, men, women, and mixed-sex groups, but there were insufficient data to draw firm conclusions on children and adolescents or on postmenopausal women. Individuals with a low or moderate baseline status responded significantly to supplementation. Data from 2 studies suggest that individuals with high baseline status do not respond to supplementation, but further studies are required. Sulfate, gluconate, and acetate all elicited a significant response, although there were only 2 studies of acetate. Secondary analysis revealed that all levels of zinc supplementation resulted in a significant increase in plasma zinc concentration and that the WMD in plasma zinc concentration increased in a dose-dependent manner ( Figure 2) .
All 11 depletion studies included in this review were B/A studies (Table 2 ) with between 5 and 15 participants per arm, including 7 studies of males, 2 studies of females, and 1 mixedsex group study. As with the supplementation studies, most trials were carried out with adults (8 studies, 59 participants), with one study in 5 postmenopausal women (58) and one study in 15 elderly people (53) . All participants had moderate baseline plasma zinc concentrations. However, failure to meet the minimal criteria for the severe and marginal intake categories precluded a definitive conclusion regarding the efficacy of plasma zinc concentration as a biomarker of zinc depletion. The subgroup analysis revealed a significant fall in plasma zinc concentration in response to a marginally depleted diet ( Figure 2 ). Overall, plasma zinc appears to be a good marker of zinc status in all subgroupings for which we have sufficient studies to judge.
Urinary zinc excretion
Data on the response of urinary zinc excretion to changes in dietary intake were extracted from 5 supplementation and 4 depletion studies, comprising 6 studies in adults (47 individuals from supplementation studies and 25 individuals from depletion studies), 2 studies in elderly people (both supplemented, with a total of 326 participants), and one depletion study in postmenopausal women (5 participants). However, the units used for supplementation studies (mmol/mol creatinine) differed from those in the depletion studies (mmol/d), so only the supplementation studies could be pooled. Primary analysis (highest dose arm and longest duration for each included study) of the supplementation studies revealed a significant effect of zinc intake on urinary zinc excretion (WMD: 0.31 mmol/mol creatinine; 95% CI: 0.20, 0.43) without important heterogeneity (I 2 ¼ 0%) and was supported by depletion studies (WMD: 3.89 lmol/d; 95% CI: 1.01, 6.76; I 2 ¼ 93%). M, exclusively male group; F, exclusively female group; X, mixed group; RCT p, randomized controlled trial-parallel; RCT c, randomized controlled trial-crossover study; B/A, before-after study; N/A, not available; Pl, plasma; ALAD, amino levulinic acid dehydratase; E, erythrocytes; MNC, mononuclear cells; Pl ALP, plasma alkaline phosphatase; PMNC, polymorphonuclear cells; Plat, platelet; E MT, erythrocyte metallothionein; L ecto-5#-NT, ecto-5#-nucleotidase; L, lymphocyte; monocyte MT cDNA, monocyte metallothionein cDNA; Pl EC-SOD, plasma extracellular superoxide dismutase.
2 Study 1. (Figure 3) . The data do suggest a dose response (see Table S2 under ''Supplemental data'' in the online issue).
Significant responses were recorded in studies of adults, the elderly, males, mixed-sex groups, and females and in those with a low or moderate zinc status at baseline; however, there were enough studies (!3) and participants (!50) to declare urinary zinc a useful marker of zinc status only in those with moderate zinc status at baseline (see Table S2 under ''Supplemental data'' in the online issue).
Erythrocyte zinc concentration
A total of 5 supplementation and 2 depletion studies reported values for erythrocyte zinc concentration. Neither primary analysis ( Figure S2 under ''Supplemental data'' in the online issue) nor any individual study suggested a response of this biomarker to changes in zinc intake (for more subgroup analysis details, see Table S3 under ''Supplemental data'' in the online issue).
Mononuclear cell zinc concentration
Five studies, including 95 participants, assessed the effect of the change in zinc intake on mononuclear cell zinc concentration. Pooling these 5 studies suggested that this is not a useful biomarker of zinc status (WMD: 20.05 lmol/10 10 cells; 95% CI: 20.21, 0.11; I 2 ¼ 38%).
Polymorphonuclear cell zinc concentration
Five supplementation trials and one depletion study that measured polymorphonuclear cells (PMNCs) as a biomarker of zinc status were identified. Population groups represented in the studies included adults (2 studies) and elderly persons (4 studies). Individual studies were variable, which suggests both significantly positive and negative effects of increased zinc status on PMNC zinc concentration. Neither primary ( Figure S3 under ''Supplemental data'' in the online issue) nor secondary analyses (Table S4 under ''Supplemental data'' in the online issue) revealed any significant response of this biomarker to changes in zinc intake. Our data suggest that PMNC zinc concentration is not a useful marker of zinc status.
Platelet zinc concentration
Five studies that measured platelet zinc concentration-2 RCT supplementation studies and 3 depletion B/A studies-were identified. Of the supplementation studies, there were data for each of the following intake ranges: 15-25 mg/d (21), 26-50 mg/d (47), and 51-100 mg/d (21) . Of the depletion studies, there was one in the moderate range of depletion (58) and 2 in the marginal range (57, 60) . The primary analysis, combining data from supplementation and depletion studies, did not reveal a significant response to changes in dietary zinc intake (WMD: 0.09 nmol/10 9 cells; 95% CI: 21.12, 1.30; I 2 ¼ 76%; Figure S4 under ''Supplemental data'' in the online supplement).
Hair zinc concentration
Data were analyzed from 3 RCT supplementation studies, which included a total of 93 adult participants with either low or moderate baseline status and intakes in the ranges of 15-25, 26-50, and 51-100 mg/d. Primary analysis revealed that hair zinc (20) Randomized; N/A Lack of compliance, illness [8] (Figure 4 ). Insufficient data precluded subgroup analyses.
Plasma alkaline phosphatase activity
Six studies investigating the response of plasma alkaline phosphatase activity to changes in zinc intake were included: 3 supplementation (RCTs) and 3 depletion (B/A) studies. Overall, the primary analysis (combining the supplementation and depletion trials) revealed no significant effect of zinc intakes on plasma alkaline phosphatase activity (WMD: 4.14 IU/L; 95% CI: 22.38, 10.66; I 2 ¼ 56.6%; Figure S5 under ''Supplemental data'' in the online issue), which suggests that this is not a useful zinc biomarker. Subgrouping also did not reveal any groups in which this was a clearly useful biomarker of zinc status (Table  S5 under ''Supplemental data'' in the online issue).
Other potential markers
We found at least one study each to assess the effects of zinc supplementation or depletion on the following potential zinc biomarkers: aminolevulinic acid dehydratase, erythrocyte metallothionein, monocyte metallothionein cDNA, salivary zinc, salivary-sediment zinc, mixed-saliva zinc, plasma extracellular superoxide dismutase, lymphocyte zinc, lymphocyte ecto-5#-nucleotidase, nail zinc, plasma angiotensin-converting enzyme, neutrophil zinc, T lymphocyte metallothionein 22A mRNA, plasma 5#-nucleotidase, endogenous zinc excretion, plasma zinc flux, exchangeable zinc pool, carbonic anhydrase, fecal zinc, To claim that a biomarker was effective (ie, reflected change in status) within a review, there had to be the following: 1) statistical significance within a forest plot (95% CI did not include 0 or P , 0.05), 2) !3 trials contributing data, and 3) !50 participants contributing data in the intervention arm, control arm, or both. To claim that a biomarker was ineffective, there had to be the following: 1) a lack of statistical significance within a forest plot (95% CI included 0 or P ! 0.05); 2) !3 trials contributing data; 3) !50 participants contributing data in the intervention arm, control arm, or both; and 4) roughly similar study results (acceptable heterogeneity levels so that I 2 ,50%). RBC, red blood cell; N/A, no available data.
neutrophil a-D-mannosidase, neutrophil alkaline phosphatase, erythrocyte membrane zinc, erythrocyte membrane alkaline phosphatase, and erythrocyte membrane NP. However, there were not enough eligible studies of these markers to allow us to decide whether they were effective markers of zinc status.
DISCUSSION
Data were extracted and analyzed on 32 potential biomarkers from 46 publications. Plasma zinc concentration responded to dietary manipulation in adults, women, men, pregnant and lactating women, the elderly, and those at low and moderate baseline zinc status and in both depletion and supplementation studies. Urinary zinc excretion also appeared to respond to change in zinc status for all groups for which we had data, but with fewer studies there were fewer subgroupings with enough studies to make a clear decision about urinary zinc response. Hair zinc concentration also responded to zinc supplementation, but there were insufficient studies to assess in which subgroups these may be effective markers. For platelet, PMNC, mononuclear cell, and erythrocyte zinc concentration and alkaline phosphatase activity, there were sufficient data to judge them as likely to be ineffective as biomarkers of zinc status.
More high-quality studies are required to assess the effects of most potential zinc biomarkers and in a variety of populations. Ideally, these would be highly controlled studies or RCTs, with clearly presented methodology indicating that they are at low risk of bias. Studies need to describe their randomization methodology, clearly describe the numbers of dropouts or exclusions and the reasons for their cessation of inclusion, check compliance, and report the results of such checks.
The majority of studies identified and included in this review were zinc supplementation studies that covered a broad range of zinc intake levels, which ranged from intakes that could be achieved through diet alone to pharmacologic doses at values of .10 times the European and US dietary recommendations. This abundant data set enabled subgroup analysis according to life stage, sex, baseline status, and dose for some of the biomarkers. Fewer zinc depletion studies were identified, and participant numbers were low compared with the supplementation trials because of the practical and ethical difficulties of conducting depletion trials. The depletion studies investigated a broad range of potential biomarkers. There were some notable gaps in the availability of data from certain population groups; in particular, there was a complete absence of data regarding infants and immigrant population groups and a paucity of studies of zinc status in adolescents.
The search for a reliable indicator for zinc has been problematic because the effective regulation of zinc homeostasis buffers the functional response to dietary deficiency and excess. The total amount of zinc present in the human body ranges from 1.5 to 2.5 mg, most of which is found intracellularly within skeletal muscle tissue (57%), bone (29%), and other tissues, including skin and organs (62) . The zinc located within these tissues has a relatively slow turnover rate and is not readily responsive to changes in dietary zinc intake. Kinetic studies suggest that only a small proportion of total body zinc ('10%) represents the ''functional pool'' (3, 63, 64) , which is composed of zinc, located within the liver and other tissues, that exchanges rapidly with the plasma. When this functional pool is depleted, zinc deficiency ensues (3).
Plasma zinc, which represents ,0.2% of total body zinc content, was the most frequently measured biomarker of zinc status, thus enabling the most comprehensive analysis of this biomarker across the subgroups. The result of the primary analysis of data from depletion and supplementation studies yielded conclusive evidence that plasma zinc concentration reflects zinc intake. However, although plasma zinc concentration responds to altered intake over short periods, the homeostatic mechanisms that act to maintain plasma zinc concentration within the physiologic range (namely, adaptive changes in efficiency of absorption and levels of endogenous excretion) may prevent high plasma concentrations from being sustained over a prolonged period.
All studies included in the analysis were undertaken in apparently healthy individuals. It is well established that plasma zinc concentration can fall in response to factors unrelated to zinc status or dietary zinc intake, including infection, inflammation, stress, or trauma. Conversely, tissue catabolism during starvation can release zinc into the circulation, causing a transient increase in circulating zinc levels. Furthermore, postprandial falls in plasma zinc concentration of 22% have been reported (65, 66) . Clearly, the interpretation of plasma zinc concentration requires knowledge of all of these possible confounders.
The reliability of plasma zinc concentration as a marker of zinc status is also dependent on the proper collection and storage of the sample, because adventitious zinc can easily be added to samples by environmental exposure and inappropriate handling of samples. Care must be taken to avoid contamination from the collection or storage vessel, hemolysis of the sample when zinc is released from the red blood cells into the plasma. The time between taking the sample and the separation of the plasma from the red blood cells can also be crucial. Guidance for the collection of plasma for zinc determination has been prepared by the International Zinc Nutrition Collaborative Group (67) .
Of all the other biomarkers evaluated in this systematic review, both 24-h urinary zinc excretion and hair zinc appear to respond to zinc supplementation, but the effect of zinc depletion is inconclusive due to insufficient data. On the basis of the results of this review, erythrocytes, PMNCs, mononuclear cells, platelet zinc, and plasma alkaline phosphatase did not appear to be useful biomarkers of zinc status.
Measurement of zinc status in vulnerable groups, such as immigrant populations in Europe whose ability to absorb zinc may be compromised by high phytate concentrations, are required. In addition, there is a notable absence of data on zinc status in infants. Although zinc depletion in children across Europe is rare, situations in which general malnutrition is present with concurrent zinc deficiency may provide opportunities to monitor the response of biomarkers to supplementation.
Further research is needed to evaluate potentially useful biomarkers, including enzymes and other zinc-binding proteins that were measured in only 1 or 2 studies and for which conclusions were unable to be drawn. Kinetic parameters measured using stable isotope techniques, including the exchangeable zinc pool, fractional zinc absorption, and endogenous zinc excretion, also have potential value in the search for biomarkers. Although stable isotope studies are expensive, technically demanding, and unsuitable for large population studies, they may be useful tools for evaluating more accessible potential biomarkers and to develop new biomarkers. At the present time, on the basis of the results of this review, plasma zinc concentration is the only biomarker of status that can be used to measure zinc status in individuals with either a low or a high supply of dietary zinc, but with many limitations and constraints. Urinary zinc excretion (24 h) and hair zinc can provide useful information on zinc status in zinc-supplemented individuals, but whether these reflect zinc status in depleted individuals is not certain. It is clear that there is an urgent need to develop new biomarkers of zinc status. (Other articles in this supplement to the Journal include references 15 and 68-74.) 
